Accessibility Menu
Arrowhead Pharmaceuticals Stock Quote

Arrowhead Pharmaceuticals (NASDAQ: ARWR)

$38.06
(-1.1%)
-0.41
Price as of October 21, 2025, 3:58 p.m. ET

KEY DATA POINTS

Current Price
$38.03
Daily Change
(-1.1%) $0.41
Day's Range
$38.02 - $39.56
Previous Close
$38.03
Open
$38.45
Beta
1.63
Volume
1,969,601
Average Volume
2,419,838
Market Cap
5.3B
Market Cap / Employee
$38.03M
52wk Range
$9.57 - $40.29
Revenue
-
Gross Margin
0.96%
Dividend Yield
N/A
EPS
-$1.26
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Arrowhead Pharmaceuticals Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
ARWR+85.6%-35.06%-8.27%-26%
S&P+15.06%+95.03%+14.29%+501%

Arrowhead Pharmaceuticals Company Info

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

News & Analysis

The Fool has written over 100 articles on Arrowhead Pharmaceuticals.

Financial Health

General

Q2 2025YOY Change
Revenue$27.77M0.0%
Gross Profit$21.54M550.5%
Gross Margin77.59%0.0%
Market Cap$2.18B-32.4%
Market Cap / Employee$3.58M0.0%
Employees6090.0%
Net Income-$178.65M-2.7%
EBITDA-$159.33M7.0%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$129.79M87.0%
Accounts Receivable$9.70M0.0%
Inventory00.0%

Liabilities

Q2 2025YOY Change
Long Term Debt$666.28M48.7%
Short Term Debt$47.01M676.6%

Ratios

Q2 2025YOY Change
Return On Assets-13.11%51.0%
Return On Invested Capital-35.41%-17.2%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$152.08M-17.1%
Operating Free Cash Flow-$149.72M-29.7%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book7.2812.6130.423.19-52.13%
Price to Sales678.45938.863.143.83-97.67%
Price to Tangible Book Value7.4813.2235.993.23-52.52%
Price to Free Cash Flow TTM372.79-
Enterprise Value to EBITDA-16.45-17.093.50-12.60-33.65%
Free Cash Flow Yield0.3%-
Return on Equity-262.5%-600.7%-24.7%-34.8%-77.53%
Total Debt$851.91M$872.05M$740.51M$713.29M57.07%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.